Medical, endoscopic, and surgical therapies for the treatment of rectal cuffitis in ulcerative colitis patients with an ileal pouch-anal anastomosis: a systematic review
Patients who undergo ileal pouch-anal anastomosis (IPAA) without mucosectomy are left with a rectal cuff, which can develop inflammation known as cuffitis. Treatment of cuffitis typically includes mesalamine suppositories or corticosteroids, but individuals with refractory cuffitis may require advanced therapies, endoscopic intervention, or surgical intervention. The aim of this review is to summarize the existing literature regarding treatments options for cuffitis. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Joseph Powers, Emma Dester, Mary Schleicher, Benjamin Cohen, Bret Lashner, Andrei Ivanov, Tracy Hull, Katherine Falloon, Taha Qazi Source Type: research
Multimodal prehabilitation may improve surgical outcomes for patients with inflammatory bowel disease
Surgery is associated with loss of lean body mass and physical deconditioning, which can delay healing and lead to complications. Multimodal prehabilitation (PH) with nutrition optimization and physical therapy improves outcomes after cancer surgery. However, the effects of prehabilitation for inflammatory bowel disease (IBD) surgery are not established. We aimed to assess surgical outcomes among IBD patients exposed to prehabilitation relative to no prehabilitation. METHODS: We conducted a case-controlled study of the impact of prehabilitation in patients with IBD who underwent major abdominal surgery for Crohn ’s disea...
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Rebecca Wernick, Kelly Issokson, Andrea Banty, Viankail Cedillo Castelan, Colleen Gwarnicki, Theodore Solomon, Lilly Martirosyan, Pamela Roberts, Mae Murakami, Andrea Wise, Melissa Hampton, Karen Zaghiyan, Yosef Nasseri, Phil Fleshner, Shervin Rabizadeh, Source Type: research
Multiple biosimilar infliximab switching is not associated with disease flare in inflammatory bowel disease: a real-world effectiveness analyses in a national u.s. cohort
Infliximab (IFX) biosimilars are available for inflammatory bowel disease (IBD). Many options of IFX biosimilars exist, however there is a paucity of data on the safety and efficacy of switching between multiple IFX biosimilars. The goal of this study is to evaluate the safety and outcomes in patients who received multiple IFX biosimilars in a National U.S. Cohort of patients with IBD. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Jason Hou, Codey Pham, Anthony Xu, Shubhada Sansgiry, Varsha Modi, Akbar Waljee Source Type: research
Network meta-analysis to evaluate the comparative efficacy of biologics for maintenance treatment of adult patients with crohn ’s disease
While the therapeutic armamentarium for Crohn ’s disease (CD) is rapidly expanding, direct evidence on comparative efficacy of various treatments is lacking. CT-P13 subcutaneous (SC) provides patients with a new opportunity for maintenance treatment of their disease. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Stefan Schreiber, Silvio Danese, Jean-Frederic Colombel, Tadakazu Hisamatsu, Peter Irving, Hyunsoo Park, Dong-Hyeon Kim, Young Nam Lee, Stephen Hanauer Source Type: research
Real world effectiveness of jak inhibitor upadacitinib in ulcerative colitis versus crohn ’s disease in an ibd tertiary care center.
Upadacitinib is a selective Janus kinase inhibitor approved for the management of Crohn ’s Disease (CD) and Ulcerative Colitis (UC). (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Karan Bhatia, Uma Mahadevan Source Type: research
A randomized, placebo-controlled trial of psyllium fiber and fecal microbiota transplantation for mild to moderate ulcerative colitis
This study aimed to evaluate the role of the prebiotic psyllium in improving the clinical outcomes of FMT for mild to moderate UC, with the long-term goal of enhancing FMT as a therapeutic strategy for UC. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Lasha Gogokhia, Nancy Tran, Alexa Lavergne, Gabriela Funez-dePagnier, Grace Xiang, Ryan Warren, Manabu Nagayama, Ellen Scherl, Dana Lukin, Randy Longman Source Type: research
Efficacy, safety and immunogenicity of subcutaneous infliximab (ct-p13 sc) monotherapy versus combination therapy with immunosuppressants – post hoc analysis of liberty-cd and liberty-uc study
CT-P13 subcutaneous (SC) infliximab formulation demonstrated superiority over placebo in maintenance therapy in Crohn's disease (CD) and Ulcerative Colitis (UC) patients in two parallel 54 weeks studies (LIBERTY-CD and LIBERTY-UC). We performed a post-hoc subgroup analysis comparing patients treated with CT-P13 SC with and without combination immunosuppressants (IS) at baseline in CD and UC. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Stefan Schreiber, Jean-Frederic Colombel, Stephen Hanauer, William Sandborn, Bruce Sands, Silvio Danese, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Sun Hee Lee, Seul Gi Lee, Joon Ho Lee, Jong Min Kim, Si Young Yang, Jimin Lee, Ga Hee Park, Ju Hyun Lee Source Type: research
Maintenance efficacy of oral indigo naturalis for ulcerative colitis: a single-center, open-label, randomized, controlled study
Indigo naturalis (IN) is one of the herbal medicines in Chinese medicine. Recent reports have demonstrated a strong remission induction efficacy of oral IN in induction therapy for ulcerative colitis (UC), but the efficacy of IN in maintenance therapy for UC is unknown. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Yuichi Matsuno, Junji Umeno, Atsushi Hirano, Yuta Fuyuno, Tomohiro Nagasue, Shin Fujioka, Keisuke Kawasaki, Tomohiko Moriyama, Takehiro Torisu Source Type: research
Protective role of saffron to reduce inflammation and improve clinical manifestations in ulcerative colitis patients
We studied saffron as an additional intervention to improve clinical manifestations of Ulcerative colitis (UC) patients, (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Hassan Ashktorab, Roham Salman Roghani, Hassan Rohgani, Lakshmi Chirumamilla, Nasrin Farjana, Mudasir Rashid, Farshad Aduli, Angesom Kibreab, Adeyinka Laiyemo, Suryanarayana Reddy Challa, Philip Oppong-Twene, Hassan Brim Source Type: research
Subcutaneous infliximab (ct-p13 sc) dose escalation as an option for managing the loss of response in inflammatory bowel disease post hoc analysis of liberty-uc and liberty-cd study
Dose escalation of IV infliximab is an option for inflammatory bowel disease (IBD) patients who lose response after induction therapy. However, as yet, there is limited data for CT-P13 subcutaneous (SC) infliximab (CT-P13 SC) dose escalation in IBD patients. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Silvio Danese, Jean-Frederic Colombel, Stephen Hanauer, William Sandborn, Bruce Sands, Stefan Schreiber, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Sun Hee Lee, Seul Gi Lee, Joon Ho Lee, Jong Min Kim, Si Young Yang, Jimin Lee, Ga Hee Park, Ju Hyun Lee Source Type: research
The modulatory effect of prebiotic inulin-type fructans on the microbiome profile of children with inflammatory bowel disease: a double-blind randomized controlled trial
The intestinal microbiota plays a pivotal role in the inflammation associated with inflammatory bowel disease (IBD) through their interaction with the mucosal immune system. Prebiotic interventions using inulin-type fructans increase faecal and mucosal bifidobacteria as well as butyrate producing bacteria in healthy volunteers. The aim of this study was to assess the effect of a two-month oligofructose-enriched inulin (OI) supplementation on the microbiome composition, metabolome of children with IBD with subclinical disease activity. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Jessica Breton, Ceylan Tanes, Bittinger Kyle, Kelly Kachelries, Melissa Crisci, Charlene Compher, Robert Baldassano, Lindsey Albenberg Source Type: research
The burden of inflammatory bowel disease on covid-19 hospitalizations: a nationwide analysis
Inflammatory bowel disease (IBD) is a chronic systemic inflammatory process with primarily gastrointestinal (GI) manifestations, and is comprised of Crohn ’s disease (CD) and ulcerative colitis (UC). The COVID-19 pandemic was unprecedented global health crisis that had a profound impact on healthcare burden. Both IBD and COVID-19 are associated with a pro-inflammatory state, however, the relationship between the two disease states remains unclear. S ome studies suggest that IBD patients may develop more severe COVID-19 infection. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Humzah Iqbal, Rakahn Haddadin, Hasib Haidary, Patrick Zhang, Devang Prajapati Source Type: research
Cytokine multi-omics and machine learning identify mip1alpha as a novel mediator in inflammatory bowel disease
Macrophage inflammatory protein 1 alpha (MIP1a) is a proinflammatory cytokine previously related to murine models of inflammatory bowel disease (IBD), but not definitively in the human disease. MIP1a acts as a chemoattractant of immune cells from the blood to the gut mucosa. We aimed to delineate the alterations to MIP1a and macrophages in relation to a range of IBD severity. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Eileen O'Brien, Chinmay Potdar, Daniel Mulder Source Type: research
Group 3 innate lymphoid cells rely on er stress response for cytokine production in ibd
Group 3 innate lymphoid cells (ILC3s) recently emerged as important regulators and potential drug targets for IBD. However, the response of ILC3s to environmental stimuli during intestinal inflammation remains elusive. IRE1a-XBP1 serves as the regulatory hub of the endoplasmic reticulum stress response that plays a vital role in intestinal inflammation. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Siyan Cao, Matthew Ciorba, Randal Kaufman, Parakkal Deepak, Marco Colonna Source Type: research
Non-invasive determination of disease activity in crohn ’s disease by serum luminex profiling
Crohn ’s disease (CD) is a chronic inflammatory disease with a complex pathogenesis; treatment and management largely depend on disease activity assessment, which can be challenging and invasive. The aim of this study was to assess the ability of multiplex Luminex technology to identify serum cytokine a nd/or chemokine markers of disease activity. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Gabriella Raffa, Regina Tyree, Kate Carson, Margaret Allaman, Dawn Beaulieu, Robin Dalal, Baldeep Pabla, Elizabeth Scoville, Sara Horst, David Schwartz, Keith Wilson, Lori Coburn Source Type: research
